BCR-ABL tyrosine kinase inhibitor (Theseus Pharmaceuticals)

N/A

Report date: 2025/03/18 18:11:27
NME

Base Information

Drug NameBCR-ABL tyrosine kinase inhibitor (Theseus Pharmaceuticals)
Drug Alias Nametyrosine kinase inhibitor targeting BCR-ABL (Theseus)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitors
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsLeukemia, Myelogenous, ChronicPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTheseus Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesTheseus Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsLeukemia, Myelogenous, ChronicPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A